



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 6582

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

05 March 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Head & Neck Cancer (H&N), Renal Cancer (RCC) and Colorectal Cancer (CRC).

You asked:

We are researching the incidence and treatment of Head & Neck Cancer (H&N), Renal Cancer (RCC) and Colorectal Cancer (CRC). Could you please answer the following questions for patients treated by your trust?

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?

- a. Carboplatin (monotherapy or in combination with 5-FU)*
- b. Cisplatin (monotherapy or in combination with 5-FU)*
- c. Cetuximab with/without chemotherapy*
- d. Cetuximab with radiotherapy*
- e. Pembrolizumab monotherapy*
- f. Pembrolizumab with chemotherapy*
- g. Nivolumab*
- h. Docetaxel (monotherapy or in combination with 5-FU)*
- i. Fluorouracil (5FU)*
- j. Radiotherapy only*
- k. Other*

2. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma :

- a. Sunitinib*
- b. Avelumab + Axitinib*
- c. Axinitib*
- d. Cabozantinib*
- e. Everolimus*
- f. Lenvantinib + Everolimus*

- g. Nivolumab
- h. Nivolumab + Ipilimumab
- i. Pazopanib
- j. Pembrolizumab + Axitinib
- k. Sunitinib
- l. Temsirolimus
- m. Tivozanib
- n. Other

3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?

- a. Aflibercept
- b. Bevacizumab
- c. Cetuximab monotherapy
- d. Cetuximab in combination with FOLFOX or FOLFIRI
- e. Panitumumab monotherapy
- f. Panitumumab in combination with FOLFOX or FOLFIRI
- g. Nivolumab
- h. Ramucirumab
- i. Regorafenib
- j. Sorafenib

Trust response:

- 1.
- a. 2
- b. 0
- c. 1
- d. 0
- e. 2
- f. 0
- g. 2
- h. 0
- i. 0
- j. 19
- k. 1

- 2.
- a. 3
- b. 0
- c. 0
- d. 1
- e. 0
- f. 0
- g. 3
- h. 0
- i. 2
- j. 0
- k. 0
- l. 0
- m. 1

- 3.
- a. 0
- b. 0
- c. 1
- d. 12
- e. 1
- f. 1
- g. 0
- h. 0
- i. 0
- j. 0